Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)

Repurposing Diflunisal for Familial Amyloid Polyneuropathy

(2015) John L. Berk et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange

(2014) Irit Rappley et al.   BIOCHEMISTRY

Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis

(2014) J. C. Genereux et al.   EMBO JOURNAL

Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction

(2014) Selma F. Mohammed et al.   JACC-Heart Failure

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

(2013) Teresa Coelho et al.   JOURNAL OF NEUROLOGY

Stress-Independent Activation of XBP1s and/or ATF6 Reveals Three Functionally Diverse ER Proteostasis Environments

(2013) Matthew D. Shoulders et al.   Cell Reports

The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug

(2012) Steven M. Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial

(2012) T. Coelho et al.   NEUROLOGY

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

(2012) C. E. Bulawa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cardiac Amyloidosis

(2011) Rodney H. Falk   CIRCULATION

Quantification of the Thermodynamically Linked Quaternary and Tertiary Structural Stabilities of Transthyretin and Its Disease-Associated Variants: The Relationship between Stability and Amyloidosis†

(2008) Amy R. Hurshman Babbes et al.   BIOCHEMISTRY